FOLH1 and prostate carcinoma: CTCs were captured from blood of prostate cancer patients on a biofunctionalized substrate using a microfluidic probe integrated with herringbone structures for microvortex generation, and the bottom capture substrate of the herringbone microfluidic probe (HB-MFP) was functionalized with multiple biorecognition ligands; CTCs were captured efficiently from blood samples via specific EpCAM, PSMA, and PSA antigens revealing certain CTC phenotypes based on their expression levels [247].